DaVita Inc.
DaVita Inc. (DVA)
Overview
DaVita Inc. is one of the largest providers of kidney dialysis services in the world, treating patients with chronic kidney disease and end-stage renal disease (ESRD) at outpatient centers, in hospitals, and at home. Headquartered in Denver, Colorado, and trading on the NYSE under the ticker DVA, the company (whose name is derived from the Italian for "to give life") was founded in 1979, went public in 1995, and adopted the DaVita name in 2000. DaVita operates roughly 2,650 dialysis centers in the U.S. serving about 200,000 patients — around 36% of the nation's dialysis population — plus close to 600 additional centers across 14 other countries. The company employs approximately 78,000 people and generates roughly $14 billion in trailing-twelve-month revenue, with a market capitalization near $12 billion. Notably, Berkshire Hathaway holds a large equity stake in DaVita — historically over 40% of shares outstanding — making it one of Warren Buffett's largest concentrated single-company holdings.
What They Do & How They Make Money
DaVita's core business is operating outpatient dialysis clinics where patients with kidney failure receive hemodialysis treatment, typically three times a week, for the rest of their lives unless they receive a kidney transplant — a chronic, recurring, non-discretionary medical need that makes DaVita's underlying patient volume relatively stable and predictable. The company is paid on a per-treatment basis by a mix of government and commercial insurance payers: Medicare and other government programs cover roughly two-thirds of DaVita's patients and revenue (because ESRD patients qualify for Medicare regardless of age), while commercial/private insurance covers a smaller share of patients (well under half) but at reimbursement rates many multiples higher than Medicare's — meaning a small proportion of commercially-insured patients generates a disproportionate share of DaVita's actual profit. Beyond core dialysis, DaVita has expanded into integrated kidney care — value-based care arrangements where it takes on financial risk for a patient's broader health outcomes, ancillary clinical laboratory services, and international dialysis operations, both organically and through acquisitions (its ~$4.4 billion purchase of HealthCare Partners in 2012 pushed it further into integrated/value-based medical care before that business was later divested).
Business Segments
DaVita organizes its reporting primarily around geography and care setting:
- U.S. Dialysis and Related Lab Services (the large majority of revenue): DaVita's core business — operating outpatient dialysis centers across the U.S. that provide hemodialysis and peritoneal dialysis, along with related lab testing and ancillary services. This segment is further supported by DaVita's home dialysis programs, which let clinically appropriate patients dialyze at home rather than visiting a center, a lower-cost setting of growing strategic importance.
- Other — Ancillary Services and Strategic Initiatives: Includes DaVita's integrated kidney care and value-based care arrangements (where DaVita takes on risk-based contracts for managing the total cost of care for kidney patients, including pre-dialysis/CKD management), physician and hospital services, and other adjacent healthcare initiatives.
- International Dialysis: DaVita's dialysis center operations outside the U.S., spanning roughly 14 countries, which the company has grown both organically and via acquisition as it exports its clinical operating model to international markets.
Competitors
The U.S. dialysis industry is highly concentrated, with DaVita and one other company controlling the large majority of the market:
- Fresenius Medical Care — DaVita's dominant global rival and the only other company of comparable scale; together, DaVita and Fresenius operate a substantial majority of U.S. dialysis clinics, a concentration that has repeatedly drawn antitrust and regulatory scrutiny.
- Smaller regional and non-profit dialysis providers, including U.S. Renal Care, American Renal Associates (now part of Innovative Renal Care), Dialysis Clinic, Inc. (a non-profit), and various independent/physician-owned clinics.
- Emerging home-dialysis and kidney-care technology entrants, such as at-home dialysis device makers and value-based kidney care startups (e.g., Somatus, Cricket Health/InterWell Health), which compete both for patients seeking home-based treatment and for value-based care contracts with payers.
Competitive Position
DaVita's competitive position rests on scale, density, and clinical/operating expertise built over decades as one of a duopoly at the center of the U.S. dialysis market. Its large center footprint creates local density advantages — patients need a clinic near home given the frequency of treatment — which makes it difficult for new entrants to build a competing network from scratch, and gives DaVita negotiating leverage with commercial payers and suppliers. Its scale also supports investment in clinical protocols, quality outcomes tracking, and increasingly in value-based/integrated kidney care models that align DaVita's incentives with reducing costly hospitalizations, a capability smaller regional operators generally cannot replicate. The essential, non-discretionary, recurring nature of dialysis treatment (patients cannot simply stop or defer care) gives the business unusually stable demand and cash flow relative to most healthcare services companies.
Key risks and threats are significant, however. DaVita's business model is structurally dependent on a small base of commercially-insured patients to subsidize below-cost Medicare reimbursement, making it acutely exposed to shifts in payer mix, and to third-party premium-assistance programs that have faced legal and regulatory challenges over how patients are steered into commercial plans. The DaVita/Fresenius duopoly draws ongoing antitrust attention, including FTC scrutiny and private litigation (including a 2025 class-action alleging anticompetitive conduct) over market concentration and referral/steering practices. Reimbursement risk from Medicare policy changes (including the ESRD Prospective Payment System bundled rate) is a persistent overhang given how much of DaVita's volume is government-paid. Longer-term, the growth of home dialysis and, more disruptively, medical advances such as GLP-1 drugs and other interventions that could slow progression to kidney failure, or advances in transplantation and organ-growing technology, pose a structural risk to long-run in-center dialysis demand. DaVita also carries meaningful financial leverage and remains sensitive to labor costs and clinical staffing availability, which are critical to running a nationwide network of clinics safely.